@article {313131,
	title = {Hypertensive phase and early complications after Ahmed glaucoma valve implantation with intraoperative subtenon triamcinolone acetonide},
	journal = {Clin Ophthalmol},
	volume = {8},
	year = {2014},
	month = {2014},
	pages = {1311-6},
	abstract = {OBJECTIVE: To evaluate intraoperative subtenon triamcinolone acetonide (TA) as an adjunct to Ahmed glaucoma valve (AGV) implantation. DESIGN: Retrospective comparative case series. PARTICIPANTS: Forty-two consecutive cases of uncontrolled glaucoma undergoing AGV implantation: 19 eyes receiving intraoperative subtenon TA and 23 eyes that did not receive TA. METHODS: A retrospective chart review was performed on consecutive pseudophakic adult patients with uncontrolled glaucoma undergoing AGV with and without intraoperative subtenon TA injection by a single surgeon. Clinical data were collected from 42 eyes and analyzed for the first 6 months after surgery. MAIN OUTCOME MEASURES: Primary outcomes included intraocular pressure (IOP) and number of glaucoma medications prior to and after AGV implantation. The hypertensive phase (HP) was defined as an IOP measurement of greater than 21 mmHg (with or without medications) during the 6-month postoperative period that was not a result of tube obstruction, retraction, or malfunction. Postoperative complications and visual acuity were analyzed as secondary outcome measures. RESULTS: Five out of 19 (26\%) TA cases and 12 out of 23 (52\%) non-TA cases developed the HP (P=0.027). Mean IOP (14.2{\textpm}4.6 in TA cases versus [vs] 14.7{\textpm}5.0 mmHg in non-TA cases; P=0.78), and number of glaucoma medications needed (1.8{\textpm}1.3 in TA cases vs 1.6{\textpm}1.1 in the comparison group; P=0.65) were similar between both groups at 6 months. Although rates of serious complications did not differ between the groups (13\% in the TA group vs 16\% in the non-TA group), early tube erosion (n=1) and bacterial endophthalmitis (n=1) were noted with TA but not in the non-TA group. CONCLUSIONS: Subtenon TA injection during AGV implantation may decrease the occurrence of the HP but does not alter the ultimate IOP outcome and may pose increased risk of serious complications within the first 6 months of surgery.},
	issn = {1177-5467},
	doi = {10.2147/OPTH.S64257},
	author = {Turalba, Angela V and Pasquale, Louis R}
}
